109186 ⎘
Structure or type of the nucleic acid; Chemical structure; Spatial arrangement of the modifications Gapmers, i.e. of the type ===---===
Compounds and methods for reducing prion expression
#302POLYNUCLEOTIDE AGENTS TARGETING AMINOLEVULINIC ACID SYNTHASE-1 (ALAS1) AND USES THEREOF
#303METHODS OF SAFE ADMINISTRATION OF AN IRF5 ANTISENSE OLIGONUCLEOTIDE
#304POLYNUCLEOTIDE AGENTS TARGETING HYDROXYACID OXIDASE (GLYCOLATE OXIDASE, HAO1) AND METHODS OF USE THEREOF
#305METHOD FOR REDUCING THE RISK OF A CARDIOVASCULAR EVENT WITH CONJUGATED ANTISENSE COMPOUNDS TARGETING APO(A)
#306COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION
#307Monocarboxylate transporter (MCT) antisense oligonucleotide (ASO) inhibitors for use as therapeutics in the treatment of cancer
#308CHIRALLY ENRICHED OLIGOMERIC COMPOUNDS
#309OLIGONUCLEOTIDES FOR MODULATING MYH7 EXPRESSION
#310COMPOUNDS AND METHODS FOR REDUCING FXI EXPRESSION
#311Allele specific modulators of P23H rhodopsin
#312Methods for reducing LRRK2 expression
#313CHIMERIC DOUBLE-STRANDED NUCLEIC ACID
#314Antisense oligonucleotides targeting SCN2A for the treatment of SCN1A encephalopathies
#315POLYNUCLEOTIDE AGENTS TARGETING PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) AND METHODS OF USE THEREOF
#316ANTISENSE OLIGONUCLEOTIDE (ASO) MOLECULES AND USES THEREOF FOR CORONAVIRUS DISEASES
#317Compositions and methods for modulating neuronal excitability and motor behavior
#318COMPOUNDS OF CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE THEREOF
#319MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY
#320Compositions and methods for modulating PKK expression
#321Compounds and methods for modulating UBE3A-ATS
#322ANTISENSE OLIGONUCLEOTIDES TARGETING TIA1
#323LINKAGE MODIFIED OLIGOMERIC COMPOUNDS
#324Methods of improving anemias by combining agents
#325Compounds and methods for increasing STMN2 expression
#326Oligonucleotides for modulating SCN9A expression
#327Oligonucleotide Conjugates
#328Selective antisense compounds and uses thereof
#329Compositions for Modulating C9ORF72 Expression
#330MUSCLE-TARGETING COMPLEXES AND USES THEREOF
#331METHODS FOR REACTIVATING GENES ON THE INACTIVE X CHROMOSOME
#332COMPOSITIONS FOR MODULATING EXPRESSION OF C9ORF72 ANTISENSE TRANSCRIPT
#333Compositions and methods for modulating growth hormone receptor expression
#334Methods of treating cancer and/or enhancing sensitivity to cancer treatment by increasing tumor mutation burden or tumor indels
#335MODULATORS OF ENaC EXPRESSION
#336METHODS OF MODULATING ANTISENSE ACTIVITY
#337Modulation of factor 11 expression
#338Conjugated Antisense Compounds for Use in Therapy
#339METHODS FOR REDUCING C9ORF72 EXPRESSION
#340BBB-crossing lipid ligand of hetero nucleic acid
#341Methods for Improving Leptin Sensitivity for the Treatment of Obesity and Diabetes
#342Modulators of EZH2 expression
#343OLIGONUCLEOTIDES FOR MODULATING RTEL1 EXPRESSION
#344Selective Antisense Compounds and Uses Thereof
#345Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses Thereof
#346Oligonucleotides for reduction of PD-L1 expression
#347Modulation of Huntington expression
#348G-quadruplex-containing antisense oligonucleotides
#349METHODS OF MODULATING ANTISENSE ACTIVITY
#350Ischemic-lesion-site-specific gene therapy
#351COMPOSITIONS AND METHODS
#352Oligonucleotides for modulating Tau expression
#353POLYNUCLEOTIDE AGENTS TARGETING SERPINC1 (AT3) AND METHODS OF USE THEREOF
#354Thiophosphoramidites
#355MODULATORS OF GROWTH HORMONE RECEPTOR
#356COMPOSITIONS COMPRISING EICOSAPENTAENOIC ACID AND MIPOMERSEN AND METHODS OF USE THEREOF
#357Modulation of transthyretin expression
#358ANTISENSE OLIGONUCLEOTIDES TARGETING SREBP1
#359OLIGONUCLEOTIDES FOR MODULATING GSK3B EXPRESSION
#360Therapeutic oligonucleotides
#361Compositions and methods for modulating apolipoprotein (a) expression
#362Modulation of alpha synuclein expression
#363Modulators of APOL1 expression
#364Modulators of PCSK9 expression
#365Compositions for modulating Tau expression
#366Oligonucleotides for modulating TMEM106B expression
#367Modified oligonucleotides and methods of use
#368Oligonucleotide compositions and methods thereof
#369Nucleic acid complex
#370COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION
#371COMPOSITIONS AND THEIR USES DIRECTED TO HUNTINGTIN
#372Methods for modulating FMR1 expression
#373Selective antisense compounds and uses thereof
#374COMPOUNDS OF CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE THEREOF
#375METHODS OF MODULATING ANTISENSE ACTIVITY
#376ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION
#377MODULATORS OF DNM2 EXPRESSION
#378Compounds and methods for reducing SNCA expression
#379Oligomeric compounds comprising bicyclic nucleotides and uses thereof
#380Modified gapmer oligonucleotides and methods of use
#381MODULATION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 (STAT3) EXPRESSION
#382OLIGONUCLEOTIDES FOR MODULATING FNDC3B EXPRESSION
#383Angelman syndrome antisense treatment
#384Modulation of Dystrophia Myotonica-Protein Kinase (DMPK) Expression
#385Antisense oligonucleotides targeting alpha-synuclein and uses thereof
#386Modulating apolipoprotein (a) expression
#387OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF
#388Compositions for modulating SOD-1 expression
#389Oligonucleotides for inducing paternal UBE3A expression
#390GAPMER OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGE
#391ANTISENSE-BASED THERAPEUTICS FOR TARGETING HTRA1 AND METHODS OF USE
#392METHODS FOR THE PRODUCTION OF STERILE FISH AND OTHER EGG-PRODUCING AQUATIC ANIMALS AND COMPOUNDS FOR USE IN THE METHODS
#393Compositions and their uses directed to huntingtin
#394CANCER TREATMENT
#395Liposomal spherical nucleic acid (SNA) constructs presenting antisense oligonucleotides (ASO) for specific knockdown of interleukin 17 receptor mRNA
#396Oligonucleotide compositions and methods thereof
#397Gapmers and methods of using the same for the treatment of muscular dystrophy
#398Modulators of MALAT1 expression
#399ANTISENSE COMPOUNDS
#400Modulation of huntingtin expression
#401POLYNUCLEOTIDE AGENTS TARGETING PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) AND METHODS OF USE THEREOF
#402Antisense oligomers targeting PCSK9
#403Methods and compositions using RNA interference and antisense oligonucleotides for inhibition of KRAS
#404Oligonucleotides for reduction of PD-L1 expression
#405Compositions and methods for modulation of protein aggregation
#406Compositions for modulating expression of C9ORF72 antisense transcript
#407COMPOSITIONS FOR MODULATING C9ORF72 EXPRESSION
#408COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION
#409ANTISENSE OLIGONUCLEOTIDES FOR MODULATING RELA EXPRESSION
#410Allele-specific therapy for Huntington disease haplotypes
#411Compounds and methods for reducing Tau expression
#412Modulators of PCSK9 expression
#413COMPOUNDS AND METHODS FOR MODULATING TMPRSS6 EXPRESSION
#414METHOD OF TREATING KELOIDS OR HYPERTROPHIC SCARS USING ANTISENSE COMPOUNDS TARGETING CONNECTIVE TISSUE GROWTH FACTOR (CTGF)
#415MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION
#416ENA ANTISENSE OLIGONUCLEOTIDE FOR INHIBITION OF alpha-SYNUCLEIN EXPRESSION
#417COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS
#418ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION
#419METHODS AND COMPOSITIONS FOR MODULATING ALPHA-1-ANTITRYPSIN EXPRESSION
#420Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection
#421Compositions and methods for modulating growth hormone receptor expression
#422Modulation of angiopoietin-like 3 expression
#423Methods of reducing expression of x-inactivation escapee genes and autosomal genes
#424POLYNUCLEOTIDE AGENTS TARGETING SERPINC1 (AT3) AND METHODS OF USE THEREOF
#425MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPODYSTROPHY POPULATIONS
#426POLYNUCLEOTIDE AGENTS TARGETING COMPLEMENT COMPONENT C5 AND METHODS OF USE THEREOF
#427Compositions for modulating Ataxin 2 expression
#428OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF
#429Allele specific modulators of P23H rhodopsin
#430Oligonucleotides for inducing paternal UBE3A expression
#431SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF
#432COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION
#433Compounds and methods for reducing ATXN2 expression
#434MODULATION OF APOLIPOPROTEIN CIII (APOCIII) EXPRESSION
#435COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION
#436Oligonucleotides for reduction of PD-L1 expression
#437Compositions for modulating SOD-1 expression
#438Modulators of diacyglycerol acyltransferase 2 (DGAT2)
#439Methods for treating Alzheimer's disease
#440OLIGONUCLEOTIDES CONTAINING 2'-DEOXY-2'FLUORO-BETA-D-ARABINOSE NUCLEIC ACID (2'-FANA) FOR TREATMENT AND DIAGNOSIS OF RETROVIRAL DISEASES
#441Targeting human satellite II (HSATII)
#442MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS
#443Oligonucleotides for modulating Tau expression
#444Antisense oligonucleotides for inhibition of PD-L1 expression and treating cancer
#445Modulation of Factor 11 expression
#446Methods of selecting therapeutic molecules
#447ANTISENSE OLIGONUCLEOTIDES FOR MODULATING NFKB1 EXPRESSION
#448Compositions for modulating C9ORF72 expression
#449Conjugated antisense compounds and their use
#450Modulators of APOL1 expression
#451Oligomeric compounds comprising α-β-constrained nucleic acid
#452ANTISENSE OLIGONUCLEOTIDES FOR MODULATING RELB EXPRESSION
#453ANTISENSE OLIGONUCLEOTIDES FOR MODULATING NFKB2 EXPRESSION
#454Modulation of Lnc05 expression
#455MODULATION OF TMPRSS6 EXPRESSION
#456ANTISENSE OLIGONUCLEOTIDES FOR MODULATING REL EXPRESSION
#457SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF
#458ANTISENSE OLIGONUCLEOTIDES DIRECTED AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND USES THEREOF
#459Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
#460ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING
#461Oligonucleotides for inducing paternal UBE3A expression
#462Compounds and methods for enhanced cellular uptake
#463CCCTC-binding factor (CTCF) RNA interactome
#464SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF
#465CAMK2D antisense oligonucleotides and uses thereof
#466Chimeric double-stranded nucleic acid
#467Antisense compounds and uses thereof
#468Compositions for modulating C9ORF72 expression
#469TGF-beta oligonucleotide for use in treatment of ophthalmic diseases
#470Antisense oligomers targeting HOXB-AS3 long non-coding RNA
#471Modulation of TJP1 expression to regulate regeneration of heart cells
#472Modulation of huntingtin expression
#473Compounds and methods for reducing ATXN3 expression
#474Modulators of DNM2 expression
#475Modulation of prekallikrein (PKK) expression
#476Organic compositions to treat APOC3-related diseases
#477MODULATORS OF GROWTH HORMONE RECEPTOR
#478Anti-TNF compounds
#479COMPOUNDS AND METHODS FOR REDUCING TAU EXPRESSION
#480Carboxylated 2′-amino-LNA nucleotides and oligonucleotides comprising the same
#481Modulation of GYS1 expression
#482MODULATION OF TRANSTHYRETIN EXPRESSION
#483OLIGOMERIC COMPOUNDS COMPRISING BICYCLIC NUCLEOTIDES AND USES THEREOF
#484Modified RNAi polynucleotides and uses thereof
#485Compositions and methods for inhibiting expression of the ALAS1 gene
#486Allele-specific gene suppression
#487MODIFIED TGF-BETA OLIGONUCLEOTIDE FOR USE IN A METHOD OF PREVENTING AND/OR TREATING AN OPHTHALMIC DISEASE
#488Modulating the cellular stress response
#489Compositions and methods for modulating neuronal excitability and motor behavior
#490STANDARDIZED NEURONAL CELL ASSAYS FROM PRIMATE SPECIES
#491LNCRNA MEG3 for therapy and diagnosis of cardiac remodelling
#492Oligomer-conjugate complexes and their use
#493Modulating apolipoprotein (a) expression
#494METHOD FOR PROGNOSING AND REDUCING CARDIOVASCULAR DISEASE IN PATIENTS WITH KIDNEY DISEASES
#495Self-assembled 3D RNA cage nanoparticles
#496Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection
#497Methods of modulating KEAP1
#498Enhancing plasmin activity to prevent soft tissue calcification
#499Modulation of DYRK1B expression
#500Modulation of angiopoietin-like 3 expression
#501Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#502Multimeric oligonucleotide compounds
#503Methods and compositions for inhibiting PMP22 expression
#504Approach for treating inflammatory disorders
#505COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION
#506MODULATORS OF KLK3 ERNA
#507Methods for modulating Ataxin 2 expression
#508Compositions and methods for modulating angiopoietin-like 3 expression
#509Monocarboxylate transporter 4 (MCT) antisense oligonucleotide (ASO) inhibitors for use as therapeutics in the treatment of cancer
#510Anti-ADAM33 oligonucleotides and related methods
#511Methods of treating cancer by inhibition of DNA repair proteins using antisense based therapies
#512SELECTIVE REDUCTION OF ALLELIC VARIANTS
#513Polynucleotide agents targeting programmed cell death 1 ligand 1 (PD-L1) and methods of use thereof
#514Methods for reducing LRRK2 expression
#515Mobilizing leukemia cells
#516Cancer treatment
#517Methods of reducing expression of X-inactivation escapee genes and autosomal genes
#518Compositions and their uses directed to huntingtin
#519Nucleic acid nanostructures with core motifs
#520COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION
#521Chimeric double-stranded nucleic acid
#522Methods of treatment using antisense oligomers and conjugates targeting PCSK9
#523Manufacture of antisense oligomers and conjugates targeting PCSK9
#524MODULATORS OF DIACYGLYCEROL ACYLTRANSFERASE 2 (DGAT2)
#525COMPOUNDS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION FOR IMPROVING A DIABETIC PROFILE
#526Linkage modified oligomeric compounds
#527Methods and compositions for treating aging-associated impairments
#528Compositions and methods for modulating apolipoprotein (a) expression
#529Compositions and methods for modulating apolipoprotein C-III expression
#530MODULATION OF TRANSTHYRETIN EXPRESSION
#531MODULATION OF TRANSTHYRETIN EXPRESSION
#532Compositions and their uses directed to huntingtin
#533Modulation of SMN expression
#534MODULATORS OF KRAS EXPRESSION
#535Targeting microRNAs for metabolic disorders
#536Oligonucleotide conjugates
#537Oligomeric compounds comprising bicyclic nucleotides and uses thereof
#538COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS
#539MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPODYSTROPHY POPULATIONS
#540ANTISENSE DESIGN
#541ANTISENSE DESIGN
#542Methods and compositions for modlating apolipoprotein (A) expression
#543Modified TGF-beta oligonucleotides
#544METHODS AND COMPOSITIONS FOR MODULATING ALPHA-1-ANTITRYPSIN EXPRESSION
#545Modulation of TMPRSS6 expression
#546THERAPEUTIC OLIGONUCLEOTIDES
#547Antisense oligomers targeting PCSK9
#548Oligonucleotide compositions and methods thereof
#549Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (PNPLA3) and methods of use thereof
#550COMPOUNDS AND METHODS FOR MODULATING TARGET NUCLEAR AND SUB-NUCLEAR NUCLEIC ACID MOLECULES IN CELLS AND ANIMALS
#551MODULATION OF TRANSTHYRETIN EXPRESSION
#552MODULATION OF TRANSTHYRETIN EXPRESSION
#553MODULATION OF TRANSTHYRETIN EXPRESSION
#554MODULATION OF TRANSTHYRETIN EXPRESSION
#555MODULATION OF TRANSTHYRETIN EXPRESSION
#556MODULATION OF TRANSTHYRETIN EXPRESSION
#557MODULATION OF TRANSTHYRETIN EXPRESSION
#558MODULATION OF TRANSTHYRETIN EXPRESSION
#559MODULATION OF TRANSTHYRETIN EXPRESSION
#560MODULATION OF TRANSTHYRETIN EXPRESSION
#561Allele specific modulators of P23H rhodopsin
#562MODULATION OF DYSTROPHIA MYOTONICA-PROTEIN KINASE (DMPK) EXPRESSION
#563Tau antisense oligomers and uses thereof
#564Compounds and methods for increasing antisense activity
#565MODULATION OF ANGIOPOIETIN-LIKE 3 EXPRESSION
#566Methods for modulating expression of C9ORF72 antisense transcript
#567Modified oligonucleotides and methods of use
#568Stabilized STAT3 decoy oligonucleotides and uses therefor
#569Modulation of nuclear-retained RNA
#570Compounds and methods for reducing Tau expression
#571Compositions for modulating expression of C9ORF72 antisense transcript
#572Stereospecific Phosphorothioate LNA
#573Compounds and methods for modulating TMPRSS6 expression
#574Inhibitors of MYH7B and uses thereof
#575Compositions for modulating Tau expression
#576EFFECTS OF APOLIPOPROTEIN B INHIBITION ON GENE EXPRESSION PROFILES IN ANIMALS
#577Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, HAO1) and methods of use thereof
#578MODIFIED TGF-BETA2 OLIGONUCLEOTIDES
#579Modulation of huntingtin expression
#580Chimeric double-stranded nucleic acid
#581Modulation of alpha synuclein expression
#582INHIBITORS OF MIR-17-92 CLUSTER FOR ANTI-TUMOR ACTIVITY IN MULTIPLE MYELOMA AND OTHER MALIGNANCIES
#583Compositions and methods for modulating TTR expression
#584METHODS FOR MODULATING MECP2 EXPRESSION
#585Multimeric oligonucleotide compounds having non-nucleotide based cleavable linkers
#586Acyl-amino-LNA and/or hydrocarbyl-amino-LNA oligonucleotides
#587Long Non-Coding RNA For The Treatment Of Endothelial Dysfunction
#588Compositions for modulating expression of C9ORF72 antisense transcript
#589LNA Gapmer Oligonucleotides Comprising Chiral Phosphorothioate Linkages
#590Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#591COMPOUNDS AND METHODS FOR IMPROVED CELLULAR UPTAKE OF ANTISENSE COMPOUNDS
#592COMPOSITIONS AND METHODS
#593MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION
#594ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
#595Compositions for modulating C9ORF72 expression
#596Poly oligomer compound with biocleavable conjugates
#597Antisense design
#598Antisense design
#599ANTISENSE OLIGONUCLEOTIDES DIRECTED AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND USES THEREOF
#600Chiral library screen